News

The US Food and Drug Administration (USFDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric

Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or refractory

The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorization application (MAA) for sacituzumab govitecan-hziy (SG) to treat advanced breast cancer. SG is an antibody and topoisomerase

An international team led by researchers at the US National Institutes of Health (NIH) and the University of North Carolina at Chapel Hill have found that SARS-CoV-2 virus

A study led by the University of California, Los Angeles (UCLA) has identified a compound, berzosertib, which showed potential in treating SARS-CoV-2 virus which causes Covid-19. The study

Italian pharmaceutical company Fidia Farmaceutici has signed a binding agreement to acquire an integrated portfolio of anti-inflammatory drugs from Sanofi. Under the terms of the agreement, Fidia will

Zealand Pharma has announced the US Food and Drug Administration (FDA) approval of its Zegalogue (dasiglucagon) injection for the treatment of patients aged six and above with severe

US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines. Dyadic’s

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS)